Flexion Therapeutics (Nasdaq: FLXN) reported its preliminary fourth quarter earnings results after the bell today. The biopharmaceutical company's Q4 revenue is expected to be
Categories
biopharma
GW Pharma Q4 results fails to impress the street
GW Pharmaceuticals plc (Nasdaq: GWPH) stock was down about 4% in the extended hours of trading after the company missed analyst estimates
Earnings preview: GW Pharmaceuticals’ cannabis-based drug to play a major role in the future
The UK-based GW Pharmaceuticals (Nasdaq: GWPH) is set to report its fourth quarter and fiscal 2018-end results for the period ending September